Thomas Neenan

Trine Pharmaceuticals, Inc. develops and markets pharmaceutical products. It develops drugs which are used in the areas of renal, gastrointestinal and metabolic diseases. The company is headquartered in Waltham, MA.

Warwick Effect Polymers is engaged in the development and manufacture of novel, high value, and functional polymers using proprietary technologies. The Company was founded in 2001 as a spin-out from the University of Warwick. Its Living Radical Polymerization (LRP) allows precise control over the production of a wide range of complex polymers and has broad applicability in the production of novel specialized polymers for the Pharmaceutical, Biotechnology and Specialty Material industries. WEP's activities are focused in two main business areas: Biopolymers and Specialty Polymers.

GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA.

Bell Laboratories provides research and development services. It provides communications technologies including transistors, digital networking, signal processing, lasers and fiber-optic communications systems, communication satellites, cellular telephony, electronic switching of calls, touch-tone dialing and modems. The company was founded in 1925 and is headquartered in Murray Hill, NJ.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Sideris Pharmaceuticals, Inc. operated as a biopharmaceutical company. It focused on development of therapeutics for the treatment of transfusion related iron overload. The company was founded by Raymond Bergeron and Thomas Neenan on June 1, 2012 and was headquartered in Lexington, MA.

Abfero Pharmaceuticals, Inc. engages in the development of pharmaceutical products. It develops oral iron chelators for the treatment of diseases of iron-overload. The company was founded by Steven K. Burke, Raymond J. Bergeron, and Thomas X. Neenan and is headquartered in Boston, MA.